GELS

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026   LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted. 2025 Financial Highlights 2025 net revenue is expected to increase 45% to a record $4.5 million, with the increase due to the merger with Gummy USA, continued technological innovation, product line and distribution channel expansion, and strengthening direct-to-consumer and retail sales. Existing operations generated net revenue growth of approximately 25%. Direct-to-consumer product subscriptions increased 47% and Amazon "Subscribe & Save" customers increased 36% in 2025. Subscription customer growth continued to expand the company's recurring revenue stream and increase customer lifetime value while enhancing customer communications and retention. 2025 Operational Highlights At the beginning of the fourth quarter, completed the strategic merger with Florida-based Gummy USA™, a leading developer and advanced manufacturer of precision-dosed nutraceutical gummies. The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility expanded Healthy Extracts' vertical integration of R&D, outsourced manufacturing, marketing and distribution. Combined with Healthy Extracts' existing exclusive delivery systems (gel-packs and functional drinking straws), Gummy USA has unlocked a third specialized product development and marketing channel comprised of precision-dosed gummies for the nutraceutical and pharmaceutical markets. The Gummy USA Florida manufacturing facility and in-house R&D has begun to accelerate Healthy Extracts' overall product development and manufacturing process, enhance gross margins, and substantially strengthen the company's IP portfolio. Don Swanson, seasoned entrepreneur and manufacturing engineer and Gummy USA founder, was appointed CEO and chairman of Healthy Extracts. He further strengthened the management team as a recognized innovator in the fast-growing $13 billion global gummy supplement market. He invented and developed advanced, patent-pending white-label and private-label manufacturing solutions tailored for the health & wellness and pharma markets. Announced major 6 million nutraceutical gummy follow-on order from a woman's health nutraceutical leader. The gummies address a specialized need and were formulated under the guidance of the client's team of top-rated doctors, clinical professors and healthcare professionals, including board-certified internists, best-selling authors and leaders in family medicine. Launched STAT10, a revolutionary heart health formulation containing CoQ10, Berberine and Citrus Bergamot SuperFruit™. The product expanded Healthy Extracts' addressable market beyond general heart health to supporting the unmet nutritional needs of 40 million existing statin users in the U.S. Clinically formulated to support nutrients inhibited by statins, STAT10 addresses the common side effects of muscle and joint pain, weakness and tiredness often associated with statins. STAT10 ingredients have been shown in clinical research to support heart health and the nutrients inhibited by statins. Launched 4Sleep, a natural, science-based healthy sleep formulation specially designed to support deeper, more restorative rest. Introduced the WHITNEY JOHNS™ Gut Health Straw™, the world's first fiber prebiotic and probiotic delivery straw. The innovative product was developed in partnership with fitness influencer and health advocate, Whitney Johns. Designed for maximum convenience and effectiveness, the product enables consumers to easily enjoy the gut health benefits of a naturally flavored, sugar-free prebiotic and probiotic blend by simply sipping a straw-no pills, powders or hassles. The product targets the fast-growing digestive health products market that is expected to more than double to $105 billion by 2033, according to Precedence Research. Expanded partnership with Gelteq Limited (NASDAQ:GELS), the clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports. Building upon the success of a co-developed product line of on-the-go gel-pack products, Healthy Extracts has become Gelteq's exclusive North American manufacturing, storage, shipping and fulfillment partner. The deeper collaboration is expected to reduce fulfillment costs and unlock higher margin sales opportunities. Maintained top three category ranking on Amazon.com, with the strong sales and customer acquisition performance due to the company's highly optimized sales and marketing strategies. Management Commentary "In the final quarter of 2025, we achieved record-setting net revenues for the fifth quarter in a row, with this driving another record year,' stated Healthy Extracts CEO and Gummy USA founder, Don Swanson. "Our expected 45% year-over-year increase in net revenues, with 25% attributed to organic growth, reflects another M&A win along with strengthening performance across our direct-to-consumer and retail channels. Altogether, the year demonstrated how our well-tuned growth strategies continue to produce outsized results. "During the year we also advanced the development of several new products and technologies across new categories, including products featuring our new fiber drinking straw and precision-dosed gummy manufacturing technologies. The commercial launch of these products benefits from the strategic cross promotion across our growing customer base and distribution channels. "Our successful merger with Gummy USA last fall has been a strong catalyst for the transformation of our company, enabling us to execute on new growth strategies designed to expand our addressable market and strengthen our competitive position. "This has involved intensifying our focus on our long-term strategic evolution toward leadership in Nutra Pharma technologies. Our operating performance in the first quarter is expected to remain consistent with the previous quarter and up dramatically year-over-year-all firmly in line with our growth plans and capital allocation priorities. "Since the beginning of the year, we have been making great strides in our evolution into becoming a diversified platform addressing the high-growth, high-margin Nutra Pharma and Health & Beauty sectors. "For the $636 billion health and beauty category, we enjoy tremendous opportunities to leverage our formulation capabilities, new manufacturing platform, and proprietary delivery technologies for new skin, hair and nail products, as well as broader health and wellness applications. "Based upon our current commercial initiatives that include extensive new B2B customer engagement and product development, we see this category providing highly attractive opportunities to generate annualized revenue of more than $20 million by year end-or more than 4x above our current level. We believe this outlook is well supported by our current manufacturing facility and distribution capacity. "We have also been making great strides in our clinical initiatives, acquiring FDA Pharma approval, clinical study readiness, and the development of regulatory property opportunities. We expect these efforts to support future product differentiation, scientific validation, and broad commercial adoption. "Key to these efforts are our unique precision dose manufacturing capabilities and exclusive licensed delivery systems, We believe these provide valuable differentiation within the nutraceutical, Nutra Pharma and functional wellness markets. "Through our advanced dosing technologies, proprietary gummy and gel-based delivery systems, and other exclusive oral delivery formats, we continue to position Healthy Extracts for success in health science, manufacturing innovation, and scalable commercialization. "We believe we remain on track to further enhance shareholder value with our planned Nasdaq uplisting, with the Gummy USA merger and favorable capital structure helping us meet Nasdaq's listing requirements. We see the listing providing greater liquidity, institutional investor participation, more favorable M&A transactions, a higher valuation, and enable us to attract great new talent to our team. We see all of these positive elements coming into play as we work to make 2026 another stellar year for Healthy Extracts." 2026 Financial Outlook Based on existing customer commitments and anticipated growth in order flow, the new Gummy USA unit is projected to generate additional substantial revenue growth in 2026, with its manufacturing facility potentially reaching its $20 million annual revenue production capacity during the year. This compares to $4.5 million in overall net revenue for the full year of 2025, for a potential increase of more than 344%. New products across new categories and formats launched over the past year are expected to continue to drive growth with greater profitability (excluding non-cash-based expenses). New product launches are expected to benefit from the broad market channels the company has strategically invested in and developed over the last several years. The company plans to drive future growth by reinvesting its cashflow and profits into new product development, sales and marketing, greater manufacturing capacity, potential acquisitions, and the further expansion of its distribution and sales channels. Preliminary Results The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its audited 2025 results to be filed in Form 10-K with the SEC. About Healthy Extracts "Live Life Young Again" Healthy Extracts Inc. (OTCQB:HYEX) is a leader in nutraceutical innovations and precision dose gummy manufacturing. It develops, manufactures and markets proprietary, science-based supplements for brain, heart, and gut health. The platform enables clinically tested formulas and exclusive partnerships that deliver wellness solutions with measurable consumer and shareholder value. The company's Gummy USA™ subsidiary is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Its exclusive licensing proprietary patent-pending SureDose™ technology delivers superior safety, efficacy and compliance for white and private label customers. Healthy Extracts wholly owned subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. BergametNA products are the only heart health supplements distributed in North America containing Citrus Bergamot SuperFruit™, the only superfruit with the highest known concentration of polyphenols and flavonoids. Healthy Extracts has exclusive agreements for other innovative oral delivery systems that include Gelteq gel-packs and the Gut Health Straw, both of which provide superior bioavailability and ultimate consumer convenience. To learn more, go to: healthyextractsinc.com, bergametna.com, tryubn.com or gummyusa.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Gummy USA ™, BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are trademarks and registered trademarks of Healthy Extracts™ Inc. Company Contact Duke Pitts, President & COO Healthy Extracts Inc. Tel (720) 463-1004 Email contact Investor Contact CMA Investor Relations Tel (949) 432-7554 Email contact SOURCE: HEALTHY EXTRACTS INC. View the original press release on ACCESS Newswire

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform’s potential to change how medicinal cannabis is delivered and experienced by patients. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a higher peak exposure. As such, the results demonstrate that our oral gel platform enhances the delivery of lipophilic cannabinoid molecules and delivers more efficient uptake in the body. These results create a clear pathway for a potential expedited market launch of new medicinal cannabis products in Australia via the Special Access Scheme (“SAS”) which could position Gelteq for efficient entry into additional global markets. The SAS is an Australian Government program that allows authorised healthcare practitioners to prescribe medicinal cannabis products to patients without the products undergoing the full Therapeutic Goods Administration (“TGA”) approval process. As a resault, the SAS could potentially grant our oral gel platform earlier patient access and a faster pathway to market. A Major Advancement for Medicinal Cannabis Patients These results represent a meaningful step forward for patients who rely on medicinal cannabis, extracts or cannabinoids for therapeutic outcomes. Traditional products such as CBD oils and vapes often present challenges which include variable dosing, slow onset, inconsistent absorption, unpleasant taste, and inhalation-related risks. Gelteq’s oral gel platform overcomes these limitations by offering a safer, predictable and more convenient alternative. As Gelteq’s oral gel platform improves bioavailability, patients may achieve therapeutic effects with lower doses which could reduce exposure to unnecessary excipients or cannabinoids. The oral gel format enables pre-measured and precise dosing with no use of droppers and no reliance on food timing which enables treatment consistentency and greater convenience. Importantly, the gel also provides a non-invasive alternative to vaping which is expected to alleviate concerns around respiratory irritation or long-term inhalation safety. The ease of administration also makes the gel well-suited for patient groups that traditionally struggle with oils or capsules such as paediatric, geriatric, and palliative-care populations. A Potential Commercial Breakthrough for Gelteq in the Global Medicinal Cannabis Sector We believe the preliminary results could open the door to significant global commercial opportunities. Medicinal cannabis is one of the fastest-growing therapeutic markets worldwide1 and product differentiation is increasingly driven by delivery innovation. With the ability to enhance absorption, simplify dosing, and improve patient experience, Gelteq’s oral gel platform could enable cannabis producers to improve their offerings beyond conventional oils, vapes or tinctures. Importantly, the study’s outcome means that Gelteq could directly partner with medicinal cannabis companies without the need for additional studies for this product format. This could accelerate potential licensing, white-label manufacturing, and co-development opportunities across a range of cannabinoid-based products which includes CBD, THC, balanced ratios, minor cannabinoids, and even combination cannabinoid–nutraceutical formulations. The Australian government’s SAS program could also enable Gelteq to bring products to market more rapidly which could generate early revenues and establish a viable product to support broader international expansion. Positioning Gelteq as a Leader in Advanced Oral Delivery Solutions The improved bioavailability of medicinally relevant cannabinoids as delivered by our oral gel platform further validates Gelteq’s position in advanced oral-delivery technologies. By enabling a simpler and more effective cannabinoid administration, our oral gel platform aims to support the next generation of medicinal cannabis products designed around patient needs and meet modern clinical expectations. About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners across pharmaceutical, consumer health and animal health markets. The proprietary formulation technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com. Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 [email protected] Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmacokinetic study, Gelteq’s formulation demonstrated a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax). The results of the study show Gelteq’s gel-based delivery technology can significantly enhance oral bioavailability of the drug, in addition to the broad benefits of the technology in solving drug delivery, swallowing and patient compliance issues. “These results represent a major technical and commercial milestone for Gelteq,” said Nathan Givoni, CEO of Gelteq. “A 38–45% improvement in bioavailability is transformative and validates our platform’s ability to meaningfully enhance the performance of established drugs. These results also position Gelteq to pursue a much broader portfolio of pharmaceutical opportunities where similar outcomes can be achieved via our proprietary gel-based delivery technology.” Importantly, the findings extend beyond the specific antihistamine evaluated in the study. Because the test compound is water-soluble, the demonstrated bioavailability improvement provides a strong foundation for applying Gelteq’s platform across a range of other water-soluble drug classes, significantly broadening the Company’s commercial scope. “These results support our strategy of partnering and developing gel-based formulations across a wide range of therapeutically relevant compounds,” Mr. Givoni added. “We believe this opens up opportunities well beyond the antihistamine market, and into much larger drug categories where improved absorption, ease of administration, and patient-friendly formats can create immediate value.” The Company anticipates using these results to further pursue an FDA approval pathway for an antihistamine product and to increase engagement with potential pharmaceutical partners interested in next-generation drug delivery formats. About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit www.gelteq.com. Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 [email protected] Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Hydrate EZ™ delivers rapid hydration and essential electrolytes for staying refreshed, sharp and in control. Mynus Sugar™ is clinically formulated to support healthy carbohydrate metabolism. Both products feature exclusive oral delivery technology in a flavorful, super-convenient, 2-oz. gel pack format-no water or mixing required. Proprietary gel manufacturing process complements company's new exclusive SureDose™ gummy manufacturing and functional drinking straw technologies. LAS VEGAS, NV / ACCESS Newswire / September 4, 2025 / Healthy Extracts™ Inc. (OTCQB:HYEX), a platform for acquiring, developing, manufacturing and marketing science-based nutraceuticals for brain, heart, and metabolic health, has officially launch to the North American market two new breakthrough performance and wellness products featuring Gelteq's (NASDAQ:GELS) proprietary gel-based delivery system: Hydrate EZ™ and Mynus Sugar™. Designed for today's on-the-go lifestyle, Hydrate EZ™ delivers great tasting rapid hydration and essential electrolytes in a convenient 2-oz. gel pack format with twist-off cap. The no-mix, no-mess electrolyte gel is designed to keep you hydrated, energized, and balanced without sugar or caffeine. Whether you're working out, working in the yard, or just working, Hydrate EZ helps you stay focused, refreshed and in control. The great tasting Mynus Sugar™ gel-pack is a clinically formulated supplement that supports healthy post-meal carbohydrate metabolism. It is designed to reduce the amount of sugar absorbed into the bloodstream after eating carbohydrates. Like with Hydrate EZ, no water or mixing is required, just easy-to-take-along soft gel-packs that you can throw in your backpack, purse or glovebox and consume on-the-go, anytime, anywhere. Both products are the first of their kind to enter the North American nutraceutical market based on Gelteq's advanced consumable gel technology. They will be marketed and distributed by Healthy Extracts' BergametNA™, building off the subsidiary's market leadership in heart health and brain performance. The new products are available for purchase today from Bergametna.com and from the BergametNA Amazon Store. Purchases of any heart or sleep product from BergametNA.com will receive free samples of Hydrate EZ™ and Mynus Sugar™. Save an additional 20% when signing up for Subscribe & Save at Bergametna.com or enjoy a 10% limited-time discount promotion on Amazon. The launch follows the company's recently reported strong financial results, with revenue up nearly 20% in the first half of the year. The launch also builds upon the recently completed transformative merger with Gummy USA that has accelerated the company's growth outlook by more than 50% and enhanced its ability to bring disruptive health and wellness solutions to market. They are also the first products launched under the new North American distribution and fulfillment agreement signed with Australia-based Gelteq that was announced in June. The expanded partnership establishes Healthy Extracts as an operational and commercialization backbone for Gelteq's innovative products in North America. "The addition of Hydrate EZ and Mynus Sugar to our product portfolio greatly strengthens our value proposition for our customers and stakeholders," noted Healthy Extracts CEO, Duke Pitts. "It greatly broadens our target customer demographic to nearly all age groups and opens the door to vast new retail channels." "Gelteq's unique gel-based delivery system also enables us to innovate faster, market more effectively, and create new revenue streams," continued Pitts, "all which supports our long-term growth strategy." Gelteq CEO, Nathan Givoni, commented: "We are excited to see our technology launched in the U.S. through Healthy Extracts' tremendous brand strength and national reach. Hydrate EZ™ and Mynus Sugar™ are just the first of many products we are planning to bring to the U.S. market in partnership with Healthy Extracts. We believe they will create a powerful foundation for long -term growth and consumer engagement." The new product introductions demonstrate how Healthy Extracts remains focused on the highest-growth segments of the nutraceutical market. Hydrate EZ targets a hydration supplement market that is forecasted to reach $4.4 billion by 2034 in the U.S. alone, growing at a 5.0% CAGR. The demand for electrolyte supplementation follows similar growth trends. The launch of Mynus Sugar is also supported by strong industry tailwinds, with the carb blocker supplement market projected to grow at a 8.9% CAGR to reach $2.5 billion by 2033. The exclusive gel technology and new product lines complement Healthy Extracts' new exclusive functional drinking straw technology as featured in the recently launched Whitney Johns Gut Health Straw. They also complement the new SureDose™ gummy technology acquired through the recent merger with Gummy USA. Watch Hydrate EZ and Mynus Sugar launch video on Healthy Extracts' YouTube channel by clicking here. About Healthy Extracts Healthy Extracts Inc. (OTCQB:HYEX) develops, manufactures and markets proprietary, science-based supplements for brain, heart, and gut health. The platform enables clinically tested formulas and exclusive partnerships that deliver wellness solutions with measurable consumer and shareholder value. The company's Gummy USA™ subsidiary is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Its proprietary patent-pending SureDose™ technology delivers superior safety, efficacy and compliance for white and private label customers. Healthy Extracts wholly owned subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. BergametNA product feature the only heart health supplements distributed in North America containing Citrus Bergamot SuperFruit™, the only superfruit with the highest known concentration of polyphenols and flavonoids. The company also has exclusive agreements for other innovative oral delivery systems that include Gelteq gel-packs and the Gut Health Straw, both of which provide superior bioavailability and ultimate consumer convenience. To learn more, go to: healthyextractsinc.com, bergametna.com, tryubn.com or gummyusa.com. About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ:GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq's proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit www.gelteq.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Gummy USA ™, BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are trademarks and registered trademarks of Healthy Extracts™ Inc. Company Contact Duke Pitts, CEO Healthy Extracts Inc. Tel (720) 463-1004 Email contact Investor Contact CMA Investor Relations Tel (949) 432-7554 Email contact SOURCE: HEALTHY EXTRACTS INC. View the original press release on ACCESS Newswire